News

The trial was designed to evaluate the safety, tolerability and pharmacokinetics of low doses of ITI-007 in these patients. According to the company, secondary endpoints of the trial

ZS003 was a Phase 3, 753 patient, multicenter, randomized, double-blind, placebo-controlled trial that assessed the safety and efficacy of ZS-9 (sodium zirconium cyclosilicate) in treating patients with hyperkalemia,

This marks the first launch of Fycompa in the Asia region. Fycompa is a highly selective, noncompetitive AMPA receptor antagonist discovered and developed by Eisai. With epileptic seizures

The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and

The European Commission will review the opinions and make a final decision sometime in the first quarter of 2015. "The CHMP positive opinions mark an important milestone in

The project will help the company keep pace with a growing demand for the development and use of biologics, which currently represents nearly 50% of its overall pipeline.

As part of the deal, Yabao will receive exclusive rights to discover, develop and commercialise new products in China, Taiwan and Hong Kong, while MRC Technology will retain

In the coming months, the European Commission (EC) is expected to make a final decision on granting marketing authorization for Cerdelga in the European Union (EU). In August,

Victoza (liraglutide) is a once-daily human the human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. It works by stimulating the